{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:55:37Z","timestamp":1791032137335,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether vitamin D repletion of patients with primary hyperparathyroidism (PHPT) and vitamin D deficiency or insufficiency (hypovitaminosis D) has deleterious clinical and\/or biochemical effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective audit of the effect of vitamin D repletion on biochemical data in 56 patients with PHPT. Patients were treated with 50\u200a000 units of vitamin D<jats:sub>2<\/jats:sub> weekly for 8 weeks with biochemical measurements at 5 and 10 weeks, and subsequently after 12 weeks on 800 units of vitamin D<jats:sub>3<\/jats:sub> daily, and in those with hypovitaminosis D after 12 weeks of up to 100\u200a000 units of vitamin D<jats:sub>2<\/jats:sub> monthly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum calcium, albumin, phosphorus, 25-OHD, intact parathyroid hormone (PTH) and urine calcium\/creatinine (Ca\/Cr) ratios were measured before and during vitamin D therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients treated with 50 000 units of vitamin D<jats:sub>2<\/jats:sub> weekly for 8 weeks resulted in a significant increase in serum 25-OHD levels from 36.4 to 89.4\u200anmol\/l at 5 weeks (<jats:italic>P<\/jats:italic>&lt;0.0001) and 88.6\u200anmol\/l at 10 weeks (<jats:italic>P<\/jats:italic>&lt;0.0001). There were no significant changes in serum calcium. At 10 weeks, there was a non-significant decrease in serum PTH and in urine Ca\/Cr ratios. None of the patients developed any calcium-related adverse events. Subsequently, patients with subnormal 25-OHD levels on 800 units of vitamin D daily were treated for the next 12 weeks with up to 100\u200a000 units of vitamin D<jats:sub>2<\/jats:sub> monthly with normalization of serum 25-OHD in all but 4 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data fail to demonstrate any adverse effects of vitamin D repletion in PHPT.<\/jats:p><\/jats:sec>","DOI":"10.1530\/eje-08-0901","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T02:29:54Z","timestamp":1240367394000},"page":"189-193","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":54,"title":["Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D"],"prefix":"10.1093","volume":"161","author":[{"given":"J R","family":"Tucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/161\/1\/189.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/161\/1\/189.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:22:59Z","timestamp":1676391779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/161\/1\/189\/6676212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje-08-0901","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}